Lignans in treatment of cancer and other diseases

Phytochemistry Reviews

Volumn 2, Issue 3, 2003, Pages 341-362

  Lee, Kuo Hsiung ^a   Xiao, Zhiyan ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antagonism; Antitumor; Antiviral; Hepatoprotective; Lignans; Platelet Activating Factor (PAF)

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; 4' NOREPIPODOPHYLLOTOXIN; 4' NORPODOPHYLLOTOXIN; ALPHA PELTATIN; ANTINEOPLASTIC AGENT; BETA PELTATIN; CISPLATIN; COLCHICINE; CYCLOPHOSPHAMIDE; DEOXYPODOPHYLLOTOXIN; DIMETHYLISOLARICIRESINOL 2 ALPHA XYLOSE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOFOS; ETOPOSIDE; ETOPOSIDE DERIVATIVE; GL 331; INOTOPLICINE; LIGNAN DERIVATIVE; MITOPODOZIDE; PICROPODOPHYLLIC ACID; PLANT MEDICINAL PRODUCT; PODOPHENAZINE DERIVATIVE; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; TENIPOSIDE; TOP 53; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER THERAPY; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEX FORMATION; CONFERENCE PAPER; CYTOPENIA; CYTOTOXICITY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EMOTIONAL STRESS; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; FRACTIONATION; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MEDICAL RESEARCH; MYELOID LEUKEMIA; NONHUMAN; PLANT; PRIORITY JOURNAL; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 23844529912     PISSN: 15687767     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHYT.0000045495.59732.58     Document Type: Conference Paper

References (124)

1. Apers S, Paper D, Buergermeister J, Baronikova S, Van Dyck S, Lemiere G, Vlietinck A & Pieters L (2002) Antiangiogenic activity of synthetic dihydrobenzofuran lignans. J. Nat. Prod. 65: 718-720.
2. Ayres DC & Loike JD (1990) Lignans. Chemical, biological and clinical properties, Cambridge University Press, Cambridge.
3. Bastow KF, Wang HK, Cheng YC & Lee KH (1997) Antitumor agents. CLXXIII. Synthesis and evaluation of camptothecin-4β-amino-4′-O- demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents. Bioorg. Med. Chem. 5: 1481-1488.
4. Berger JM & Wang JC (1996) Recent developments in DNA topoisomerase II structure and mechanism. Curr. Opin. Struct. Biol. 6: 84-90.
5. Bohlin L & Rosén B (1996) Podophyllotoxin derivatives: drug discovery and development. Drug Discovery Today. 8: 343-351.
6. Budman DR (1996) Early studies of etoposide phosphate, a water-soluble prodrug. Semin. Oncol., 23(Suppl): 8-14.
7. Byl JAW, Cline SD, Utsugi T, Kobunai T, Yamada Y & Osheroff N (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 40: 712-718.
8. Calixto JB, Santos ARS, Filho VC & Yunes RA (1998) A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med. Res. Rev. 18: 225-258.
9. Canel C, Moraes RM, Dayan FE & Ferreira D (2000) Podophyllotoxin. Phytochemistry. 54: 115-120.
10. Castro-Faria-Neto HC, Martins MA, Silva PMR, Bozza PT, Cruz HN, de Queiroz-Paulo M, Kaplan MAC & Cordeiro RSB (1993) Pharmacological profile of epiyangambin: A furofuran lignan with PAF antagonist activity. J. Lipid Mediators 7: 1-9.
11. Castro-Faria-Neto HC, Bozza PT, Cruz HN, Silva CLM, Violante FA, Barbosa-Filho JM, Thomas G, Martins MA & Tibirica EV (1995) Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies. Planta Medica 61: 101-105.
12. Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH & Cheng YC (1991) Effect of 4β-arylamino derivatives of 4′-O-demethylpodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res. 51: 1755-1759.
13. Charlton JL (1998) Antiviral activity of lignans. J. Nat. Prod. 61: 1447-1451.
14. Chen DF, Zhang SX, Chen K, Zhou BN, Wang P, Cosentino LM & Lee KH (1996) Anti-AIDS agents-XXVI. Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior. J. Nat. Prod. 59: 1066-1068.
15. Chen DF, Zhang SX, Xie L, Xie JX, Chen K, Kashiwada Y, Zhou BN, Wang P, Cosentino LM & Lee KH (1997) Anti-AIDS agents-XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogs. Bioorg. Med. Chem. 5: 1715-1723.
16. Cho SJ, Kashiwada Y, Bastow KF, Cheng YC & Lee KH (1996a) Antitumor agents 164. Podophenazine, 2″,3″-dichloropodophenazine, benzo-podophenazine, and their 4β-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors. J. Med. Chem. 39: 1396-1402.
17. 2-GRS approach. J. Med. Chem. 39: 1383-1395.
18. Cortese F, Bhattacharyya B & Wolf J (1977) Podophyllotoxin as a probe for the colchicine binding site of tubulin. J. Biol. Chem. 252: 1134-1140.
19. Cui BL, Chai HY, Santisuk T, Reutrakul V, Farnsworth NR, Cordell GA, Pezzuto JM & Kinghorn AD (1997) Novel cytotoxic 1H-cyclopenta[b]benzofuran lignans from Aglaia elliptica. Tetrahedron 53: 17625-17632.
20. Damayanthi Y & Lown JW (1998) Podophyllotoxins: current status and recent developments. Curr. Med. Chem. 5: 205-252.
21. Finkelstein DM, Ettinger DS & Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 4: 702-709.
22. Fleming RA, Miller AA & Steward CF (1989) Etoposide: an update. Clin. Pharm. 8: 274-93.
23. Gordaliza M, Castro MA, Miguel de Corral JM, López Vázquez MZ, García PA, San Feliciano A, Garcia-Gravalos MD & Broughton H (1997) Preparation and cytotoxicity of podophyllotoxin derivatives lacking the lactone ring. Tetrahedron. 53: 15743-15760.
24. Gordaliza M, Castro MA, Miguel del Corral JM & San Feliciano A (2000a) Antitumor properties of podophyllotoxin and related compounds. Curr. Pharm. Design. 6: 1811-1839.
25. Gordaliza M, Castro MA, Miguel del Corral JM, López Vázquez MZ, García PA, Garcia-Gravalos MD & San Feliciano A (2000b) Synthesis and antineoplastic activity of cyclolignan aldehydes. Eur. J. Med. Chem. 35: 691-698.
26. Greco FA & Hainsworth JD (1996) Clinical studies with etoposide phosphate. Semin. Oncol. 23(Suppl): 45-50.
27. Hainswirth JD, Williams SD, Einhorn LH, Birch R & Greco FA (1985) Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J. Clin. Oncol. 3: 666-671.
28. Hanauske AR, Wüster KC, Depenbrock H, Peter R, Block T, Vogelsang H, Rotter M, Burk K, Fröhlich A & Rastetter J (1994) Preclinical activity of NK611, a new podophyllotoxin derivative, against clonogenic tumor cells. Proc. Am. Assoc. Cancer Res. 35: 2388.
29. Hande KR (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer. 34: 1514-1521.
30. Hartwell J (1954) The biological effects and the chemical composition of podophyllin. II. The chemistry of podophyllin. J. Natl. Cancer Inst. 14: 986-95.
31. Hikino H, Kiso Y, Wagner H & Fiebig M (1984a) Liver-protective drugs. Part 16. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Medica 50: 248-50.
32. Hikino H, Kiso Y, Taguchi H & Ikeya Y (1984b) Validity of the oriental medicines. 60. Liver-protective drugs. 11. Antihepatotoxic actions of lignoids from Schizandra chinensis fruits. Planta Medica 50: 213-18.
33. Hirano T, Gotoh M & Oka K (1994) Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 55: 1061-1069.
34. Huang TS, Shu CH, Shih YL, Huang HC, Su YC, Chao Y, Yang WK & Whang-Peng J (1996) Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett. 110: 77-85.
35. Huang TS, Shu CH, Yang WK & Whang-Peng J (1997) Activation of CDC25 phosphatase and CDC2 kinase involved GL-331 induced apoptosis. Cancer Res. 57: 2974.
36. Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC & Whang-Peng J (1999) A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut. Res. 16: 997-1002.
37. Imbert TF (1998) Discovery of podophyllotoxins. Biochimie. 80: 207-222.
38. Ishida J, Wang HK, Oyama M, Cosentino ML, Hu CQ & Lee KH (2001) Anti-AIDS agents 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives. J. Nat. Prod. 64: 958-960.
39. Ji Z, Wang HK, Bastow KF, Zhu XK, Cho SJ, Cheng YC & Lee KH (1997) Antitumor agents. 177. Design, syntheses, and biological evaluation of novel etoposide analogs bearing pyrrolecarbox-amidino group as DNA topoisomerase II inhibitors. Bioorg. Med. Chem. Lett. 7: 607-612.
40. Jung KY, Lee IS, Oh SR, Kim DS & Lee HK (1997) Lignans with platelet activating factor antagonist activity from Schisandra chinensis. Phytomedicine 4: 229-231.
41. Kaplan IW (1942) Condylomata acuminata. New Orleans Med. Surg. J. 94: 388.
42. Kashiwada Y, Nishizawa M, Yamagishi T, Tanaka T, Nonaka GI, Cosentino LM, Snider JV & Lee KH (1995a) Anti-AIDS agents, 18. Sodium and potassium salts of caffeic acid tetramers from Arnebia euchroma as anti-HIV agents. J. Nat. Prod. 58: 392-400.
43. Kashiwada Y, Bastow KF & Lee KH (1995b) Novel lignan derivatives as selective inhibitors of DNA topoisomerase II. Bioorg. Med. Chem. Lett. 5: 905-908.
44. Kelly M (1954) The biological effects and the chemical composition of podophyllin. I. The biological effects of podophyllin. J. Natl. Cancer Inst. 14: 967-86.
45. Kimura M, Suzuki J, Yamada T, Yoshizaki M, Kikuchi T, Kadota S & Matsuda S (1985) Anti-inflammatory effect of neolignans newly isolated from the crude drug "Shin-i" (flos Magnoliae). Planta Medica 51: 291-293.
46. Kiso Y, Tohkin M, Hikino H, Ikeya Y & Taguchi H (1985) Mechanism of antihepatotoxic activity of wuweizisu C and gomisin A. Planta Medica 51: 331-334.
47. Konuklugil B (1994) Lignans with anticancer activity. J. Fac. Pharm. Ankara. 23: 64-75.
48. von Krogh G (1981) Podophyllotoxin for Condylomata acuminata eradication. Clinical and experimental comparative studies on Podophyllum lignans, colchicine and 5-fluorouracil. Acta Derm. Venereol. (Stockh.) Suppl. 98: 1.
49. Kuo YH, Li SY, Huang RL, Wu MD, Huang HC & Lee KH (2001) Schizanrin B, C, D, and E, four new lignans from Kadsura matsudai and their antihepatitis activities. J. Nat. Prod. 64: 487-490.
50. Kupchan SM, Britton RW, Ziegler MF, Gilmore CJ, Restivo RJ & Bryan RF (1973) Steganacin and steganangin, novel antileukemic lignan lactones from Steganataenia araliacea. J. Am. Chem. Soc. 95: 1335-1336.
51. Lee CTL, Lin VCK, Zhang SX, Zhu XK, VanVliet D, Hu H, Beers SA, Wang ZQ, Cosentino LM, Morris-Natschke SL & Lee KH (1997) Anti-AIDS agents 29. Anti-HIV activity of modified podophyllotoxin derivatives. Bioorg. Med. Chem. Lett. 7: 2897-2902.
52. Lee IS, Jung KY, Oh SR, Park SH, Ahn KS & Lee HK (1999) Structure-activity relationships of lignans from Schisandra chinensis as platelet activating factor antagonists. Biol. Pharm. Bull. 22: 265-267.
53. Lee KH, Imakura Y, Haruna M, Beers SA, Thurston LS, Dai HJ, Chen CH, Liu SY & Cheng YC (1989) Antitumor agents 107. New cytotoxic 4-alkylamino analogues of 4′-demethylepipodophyllotoxin as inhibitors of human topoisomerase II. J. Nat. Prod. 52: 606.
54. Lee KH, Beers SA, Mori M, Wang ZQ, Kuo YH, Li L, Liu SY, Chang JY, Han FS & Cheng YC (1990) Antitumor agents 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4′-demethylepipodophyllotoxin as potent inhibitors of human topoisomerase II. J. Med. Chem. 33: 1364-1368.
55. Lee KH (1999) Novel antitumor agents from higher plants. Med. Res. Rev. 19: 569-596.
56. Lee SK, Cui B, Mehta RR, Kinghom AD & Pezzuto JM (1998) Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact. 115: 215-228.
57. Li L, Xue H & Tan R (1985) Dibenzocyclooctadiene lignans from roots and stems of Kadsura coccinea. Planta Medica. 4: 297-300.
58. Li SY, Wu MD, Wang CW, Kuo YH, Huang RL & Lee KH (2000) A novel anti-HbeAg homolignan, taiwanschirin D from Kadsura matsudai. Chem. Pharm. Bull. 48: 1992-1993.
59. Liu SY, Hwang BD, Haruna M, Imakura Y, Lee KH & Cheng YC (1989) Podophyllotoxin analogues: Effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16 resistant variants. Mol. Pharmacol. 36: 78.
60. Long BH & Casazza AM (1994) Structure-activity relationships of VP-16 analogues. Cancer Chemother. Pharmacol. 34 (suppl): S26-S31.
61. van Maanen JMS, de Vries J, Pappie D, van den Akker E, Lafleur MVM, Retel J, van der Greef J & Pinedo HM (1987) Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res. 47: 4658-1662.
62. van Maanen JMS, Lafleur MVM, Mans DRA, van den Akker E, de Ruiter C, Kootstra PR, Pappie D, de Vries J, Retel J & Pinedo HM (1988) Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double stranded ΦX174 DNA. Biochem. Pharmacol. 37: 3579-3589.
63. MacDonald TL, Lehnert EK, Loper JT, Chow KC & Ross WE (1991) On the mechanism of interaction of DNA topoisomerase II with chemotherapeutic agents. In DNA topoisomerase in cancer. Potmesil, M., Kohn, K.W., Eds., Oxford University Press: New York, pp. 119-214.
64. MacRae WD & Towers GHN (1984) Biological and activity of lignans. Phytochemistry. 23: 1207-1220.
65. Matsunaga K, Shibuya M & Ohizumi Y (1994) Graminone B, a novel lignan with vasodilative activity from Imperata cylindrica. J. Nat. Prod. 57: 1734-1736.
66. McWilliams NB, Hayes FA, Green AA, Smith EI, Nitchke R, Alltshuler GA, Shuster JJ, Castleberry RP & Vietti T (1995) Cyclophosphamide/doxorubicin vs. cisplatin/ teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study. J. Med. Pediatr. Oncol. 24: 176-80.
67. Michel G, Leyvraz S, Banre J, Aapro M, Stanhel R & Alberto P (1994) Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. Ann. Oncol. 5: 369-70.
68. Mizoguchi Y Kawada N, Ichikawa Y & Tsutsui H (1991) Effect of gomisin A in the prevention of acute hepatic failure induction. Planta Medica 57: 320-324.
69. Moraes RM, Dayan FE & Canel C (2002) The lignans of Podophyllum. Studies in Natural Products Chemistry. 26 (Bioactive Natural Products, (Part G)): 149-182.
70. Mross K, Huttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, Hossfeld DK (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother. Pharmacol. 38: 217-24.
71. O'Dwyer PJ, Leyland JB, Alonso MT, Marconi S & Wittes RE (1985) Etoposide (VP-16-213). Current status of an active anticancer drug. N. Engl. J. Med. 312: 692-700.
72. Ohse T, Ohba S, Yamamoto T, Koyano T & Umezawa K (1996) Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J. Nat. Prod. 59: 650-652.
73. Olsen EA, Abernethy ML, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, McCary M, Monroe AB, Tschen E & Wolf JEJr (1991) A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J. Am. Acad. Dermatol. 24: 738-43.
74. Pagani O, Zucchetti M, Sessa C, De Jong J, D'Incalci M, De Fusco M, Kaeser-Froehlich A, Hanauske A & Cavalli F (1996) Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother. Pharmacol. 38: 541-547.
75. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E & Janssen PAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470-474.
76. Pieters L, De Bruyne T, Claeys M, Vlietinck A, Calomme M & Vanden Berghe D (1993) Isolation of a dihydrobenzofuran lignan from South American dragon's blood (Croton spp.) as an inhibitor of cell proliferation. J. Nat. Prod. 56: 899-906.
77. Pieters L, Van Dyck S, Gao M, Bai R, Hamel E, Vlietinck A & Lemiere G (1999) Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization. J. Med. Chem. 42: 5475-5481.
78. Potterat O (1997) Antioxidants and free radical scavengers of natural origin. Curr. Org. Chem. 1: 415-440.
79. Pui CH, Relling M & Rivera G (1995) Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 9: 1990-1996.
80. Rickard SE & Thompson LU (1997) Phytoestrogens and lignans: effects on reproduction and chronic disease. ACS Symposium Series. 662: 273-293.
81. Ríos JL, Giner RM & Prieto JM (2002) New findings on the bioactivity of lignans. Studies in Nat. Prod. 26 (Part G): 183-292.
82. Ross W, Rowe T, Glisson B, Yalowich J & Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res, 44: 5857-5860.
83. Sackett DL (1993) Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharm. Ther. 59: 163-228.
84. Saito H, Yoshikawa H, Nishimura Y, Kondo S, Takeuchi T & Umezawa H (1986) Studies on lignan lactone antitumor agents II. Synthesis of N-alkylamino- and 2,6-dideoxy-2-aminoglycosidic lignan variants related to podophyllotoxin. Chem. Pharm. Bull. 34: 3741-3746.
85. Saulnier MG, Senter PD & Kadow JF (1989) Preparation of podophyllotoxin glycosides as antitumor agents and pharmaceutical compositions containing them. Brit. UK Pat. Appl. GB 2,207,674A.
86. Schiff, PB (1978) Steganacin: an inhibitor of Hela cell growth and microtubule assembly in vitro. Biochem. Biophys. Res. Comm. 85: 737-746.
87. Schröder HC, Mertz H, Steffen R, Müller WEG, Sarin PS, Trumm S, Schulz J & Eich E (1990) Differential in vitro activity of natural lignans. Z. Naturforsch. C 45: 1215-1221.
88. Shen TY & Hussaini IM (1990) Kadsurenone and other related lignans as antagonists of platelet-activating factor receptor. Methods Enzymol. 187: 446-454.
89. Shen TY (1991) Chemical and biochemical characterization of lignan analogs as novel PAF receptor antagonists. Lipids 26: 1154-1156.
90. Shi Q, Wang HK, Bastow KF, Tachibana Y, Chen K, Lee FY & Lee KH (2001) Antitumor agents 210. Synthesis and evaluation of taxoid- epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg. Med. Chem. 9: 2999-3004.
91. Sinha BK & Trush MA (1983) Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation. Biochem. Pharmacol. 32: 3495-3498.
92. Subrahmanyam D, Renuka B, Rao CVL, Sagar PS, Deevi DS, Babu JM & Vyas K (1998) Novel D-ring analogs of podophyllotoxin as potent anti-cancer agents. Bioorg. Med. Chem. Lett. 8: 1391-1396.
93. Takasaki M, Konoshima T, Yasuda I, Hamano T & Tokuda H (1997) Inhibitory effects of Shouseiryu-to on two-stage carcinogenesis. II. Anti-tumor-promoting activities of lignans from Asiasarum heterotropoides var. mandshuricum. Biol. Pharm. Bull. 20: 776-780.
94. Takashima J, Asano S & Ohsaki A (2002) Mururins A-C, three new lignoids from Brosimum acutifolium and their protein kinase inhibitory activity. Planta Medica 68: 621-625.
95. Terada T, Fujimoto K, Nomura M, Yamashita J, Wierzba K, Yamazaki R, Shibata J, Sugimoto Y, Yamada Y, Kobunai T, Takeda S, Minami Y, Yoshida K & Yamaguchi H (1993) Antitumor agents 3. Synthesis and biological activity of 4β-alkyl derivatives containing hydroxyl, amino, and amido groups of 4′-O-demethyl-4-deoxypodophyllotoxin as antitumor agents. J. Med. Chem. 36: 1689-1699.
96. Tomioka K, Ishiguro T, Mizuguchi H, Komeshima N, Koga K, Tsukagoshi S, Tsuruo T, Tashiro T, Tanida S & Kishi T (1991) Abosolute structure-cytotoxic activity relationships of steganacin congeners and analogues. J. Med. Chem. 34: 54-57.
97. Tramontano E & Cheng YC (1992) HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharmacol. 43: 1371-1376.
98. Tsai IL, Hsieh CF, Duh CY & Chen IS (1996) Cytotoxic neolignans from Persea obovatifolia. Phytochemistry 43: 1261-1263.
99. Tsai IL, Hsieh CF & Duh CY (1998) Additional cytotoxic neolignans from Persea obovatifolia. Phytochemistry 48: 1371-1375.
100. Tsukamoto H, Hisada S & Nishibe S (1984a) Lignans from bark of Fraxinus mandshurica var. japonica and F. japonica. Chem. Pharm. Bull. 32: 4482-9.
101. Tsukamoto H, Hisada S & Nishibe S (1984b) Lignans from bark of the Olea plants. I. Chem. Pharm. Bull. 32: 2730-5.
102. Utsugi T, Shibata H, Kumio S, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T & Yamada Y (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res. 56: 2809-2814.
103. VanVliet DS, Tachibana Y, Bastow KF, Huang ES & Lee KH (2001) Antitumor agents. 207. Design, synthesis, and biological testing of 4-anilino-2-fluoro-4′-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents. J. Med. Chem. 44: 1422-1428.
104. Wahala K, Makela T, Backstrom R, Brunow G & Hase T (1986) Synthesis of the [2H]-labeled urinary lignans, enterolactone and enterodiol, and the phytoestrogen daidzein and its metabolites equol and O-demethylangolensin. J. Chem. Soc. Perkin Trans. I. 1: 95-8.
105. Wang JZ, Tian X, Tsumora H, Shimura K, & Ito H (1993) Antitumor activity of a new low immunosuppressive derivative of podophyllotoxin (GP-11) and its mechanisms. Anticancer Drug Des. 8: 193-202.
106. Wang ZQ, Kuo YH, Schnur D, Bowen P, Liu SY, Han FS, Chang IY, Cheng YC & Lee KH (1990) Antitumor agents 113. New 4β-arylamino derivatives of 4′-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human topoisomerase II. J. Med. Chem. 33: 2660-2666.
107. Ward S (1993) Lignans, neolignans, and related compounds. Natural Products Reports 10: 1-28.
108. Ward S (1995) Lignans, neolignans, and related compounds. Natural Products Reports 12: 183-205.
109. Ward S (1997) Lignans, neolignans, and related compounds. Natural Products Reports 14: 43-74.
110. Ward S (1999) Lignans, neolignans, and related compounds. Natural Products Reports 16: 75-96.
111. Whiting DA (1985) Lignans, neolignans, and related compounds. Natural Products Reports 2: 191-211.
112. Whiting DA (1987) Lignans, neolignans, and related compounds. Natural Products Reports 4: 499-525.
113. Whiting DA (1990) Lignans, neolignans, and related compounds. Natural Products Reports 7: 349-64.
114. Wickramaratne DB, Pengsuparp T, Mar W, Chai HB, Chagwedera TE, Beecher CW, Farnsworth NR, Kinghorn AD, Pezzuto JM & Cordll GA (1993) Novel antimitotic dibenzocyclo-octadiene lignan constituents of the stem bark of Steganotaenia araliacea. J. Nat. Prod. 56: 2083-2090.
115. Wu YC, Chang GY, Ko FN & Teng CM (1995) Bioactive constituents from the stems of Annona montana. Planta Med. 61: 146-149.
116. Xiao Z, Xiao YD, Feng J, Golbraikh A, Tropsha A & Lee KH (2002) Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method. J. Med. Chem. 45: 2294.
117. Xiao Z, Bastow KF, Vance JR & Lee KH (2004a) Antitumor agents. 227. Studies on novel 4′-O-demethyl-epipodophyllotoxins as antitumor agents targeting topoisomerase II. Bioorg. Med. Chem. Accepted.
118. Xiao Z, Bastow KF, Vance JR, Sidwell RS, Wang KH, Chen MS, Shi Q & Lee KH (2004b) Antitumor agents. 234. Design, synthesis and biological evaluation of novel 4β-[4″-benzamido)-amino]-4′-O-demethyl- epipodophyllotoxin derivatives. J. Med. Chem. Submitted.
119. Xie L, Xie JX, Kashiwada Y, Cosentino LM, Liu SH, Pai RB, Cheng YC & Lee KH (1995) Anti-AIDS Agents 17. New brominated hexahydroxybiphenyl derivatives as potent Anti-HIV agents. J. Med. Chem. 38: 3003-3008.
120. Yang LM, Lin SJ, Yang TH & Lee KH (1996) Synthesis and Anti-HIV activity of dibenzylbutyrolactone lignans. Bioorg. Med. Chem. Lett. 6: 941-944.
121. Zavala F, Guenard D, Robin JP & Brown E (1980) Structure-antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (±)-isodeoxypodophyllotoxin. J. Med. Chem. 23: 546-549.
122. Zhang SX, Chen K, Liu XJ, Zhang DC, Tao-Wiedmann TW, Leu SL, McPhail AT & Lee KH (1995) Isolation and structural elucidation of three new neolignans, puberulins A, B and C, from Piper puberulum, as platelet activating factor receptor antagonists. J. Nat. Prod. 58: 540-7.
123. Zhang YL & Lee KH (1994) Recent progress in the development of novel antitumor etoposide analogs. Chin. Pharm. J. 46: 319-369.
124. Zhou XM, Lee KJH, Cheng J, Wu SS, Chen HX, Guo X, Cheng YC & Lee KH (1994) Antitumor agents. 144. New γ-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II. J. Med. Chem. 37: 287-292.